INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6. A total of 41 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $148,000 | -88.1% | 181,000 | -88.5% | 0.00% | – |
| Q4 2020 | $1,247,000 | -16.3% | 1,569,000 | -15.2% | 0.00% | – |
| Q3 2020 | $1,490,000 | -45.5% | 1,851,000 | -49.8% | 0.00% | -100.0% |
| Q2 2020 | $2,732,000 | -38.6% | 3,685,000 | -32.8% | 0.00% | 0.0% |
| Q1 2020 | $4,453,000 | -12.8% | 5,480,000 | +8.8% | 0.00% | 0.0% |
| Q4 2019 | $5,104,000 | -43.9% | 5,036,000 | -52.4% | 0.00% | -50.0% |
| Q3 2019 | $9,104,000 | -10.4% | 10,584,000 | -7.0% | 0.00% | 0.0% |
| Q2 2019 | $10,157,000 | -9.7% | 11,383,000 | -0.2% | 0.00% | 0.0% |
| Q1 2019 | $11,245,000 | -0.6% | 11,410,000 | -8.5% | 0.00% | -33.3% |
| Q4 2018 | $11,312,000 | -9.3% | 12,465,000 | +0.7% | 0.00% | +50.0% |
| Q3 2018 | $12,469,000 | +24.6% | 12,373,000 | +2.6% | 0.00% | 0.0% |
| Q2 2018 | $10,006,000 | +2.2% | 12,056,000 | -0.7% | 0.00% | 0.0% |
| Q1 2018 | $9,786,000 | -18.6% | 12,141,000 | -18.2% | 0.00% | -33.3% |
| Q4 2017 | $12,026,000 | +15.7% | 14,847,000 | +12.2% | 0.00% | +50.0% |
| Q3 2017 | $10,397,000 | -14.4% | 13,232,000 | +7.0% | 0.00% | -33.3% |
| Q2 2017 | $12,151,000 | +370.1% | 12,367,000 | +347.4% | 0.00% | +200.0% |
| Q1 2017 | $2,585,000 | -71.1% | 2,764,000 | -72.2% | 0.00% | -50.0% |
| Q4 2016 | $8,953,000 | -16.3% | 9,933,000 | +4.0% | 0.00% | -33.3% |
| Q3 2016 | $10,702,000 | – | 9,552,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|